Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS)

Heart
C H LeeM Cortellaro

Abstract

To investigate the effect on risk of major adverse cardiac events (MACE) of lipid lowering treatment with fluvastatin 80 mg/day after a first percutaneous coronary intervention in patients with stable and unstable angina. This prespecified subgroup analysis of the LIPS (Lescol intervention prevention study) analysed 1658 patients with documented diagnosis; 824 had unstable angina (417 randomly assigned to fluvastatin, 407 to placebo) and 834 had stable angina (including silent ischaemia; fluvastatin, 418; placebo, 416). Median follow up was 3.9 years. There was no significant effect of anginal status on long term risk of MACE. Fluvastatin treatment reduced the risk of MACE by 28% compared with placebo (p = 0.03) among patients with unstable angina, with no difference between patients with stable and patients with unstable angina (relative risk 1.07, 95% confidence interval 0.87 to 1.30, p = 0.53). Fluvastatin reduced coronary atherosclerotic events (MACE excluding restenosis) by 36% (p = 0.006) among patients with unstable angina and 31% (p = 0.02) among patients with stable angina. Fluvastatin caused similar reductions in total cholesterol and low density lipoprotein cholesterol concentrations in both patient groups. Treatment...Continue Reading

References

Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jan 11, 2001·International Journal of Cardiology·T PrzewlockiA Sokolowski
Apr 13, 2001·JAMA : the Journal of the American Medical Association·G G SchwartzUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Jan 23, 2002·Cerebrovascular Diseases·Ludovic Drouet
Apr 11, 2002·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·N FiottiC Giansante
Apr 30, 2002·Lancet·UNKNOWN LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Jun 22, 2002·JAMA : the Journal of the American Medical Association·Patrick W J C SerruysUNKNOWN Lescol Intervention Prevention Study (LIPS) Investigators

❮ Previous
Next ❯

Citations

Mar 30, 2005·International Anesthesiology Clinics·Jae Woo Lee
Mar 1, 2006·Critical Care Medicine·Massimo ChelloElvio Covino
Dec 21, 2005·Heart·UNKNOWN British Cardiac SocietyUNKNOWN Stroke Association
Dec 17, 2010·European Journal of Medical Research·M R PreuschR Kranzhöfer
Jun 17, 2009·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Pedro A LemosEulógio E Martinez
Apr 2, 2005·Current Medical Research and Opinion·Evagelos N LiberopoulosMoses S Elisaf
Sep 12, 2013·Current Medical Research and Opinion·Alan Jones
Jul 12, 2005·Pharmacotherapy·Nicole S CulhaneJeannine R Skae
Mar 11, 2008·The American Journal of Cardiology·Peter WenaweserBernhard Meier
Jun 19, 2012·The Journal of Thoracic and Cardiovascular Surgery·Toshihiro FukuiShuichiro Takanashi
Mar 7, 2018·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
May 27, 2006·Coronary Artery Disease·Donna M Polk, Karol Watson

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.